Monitor the webcasts for any strategic commentary on setmelanotide label expansion or pipeline progress, but this filing alone does not warrant a trading action.
RYTM drugs
RYTM drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 26 $89.82entry
- T+1 · 6mo ago +1.78%α +1.77% · $91.42
- T+5 · 6mo ago −2.17%α −3.25% · $87.87
- T+20 · 5mo ago +20.22%α +22.17% · $107.99
- T+60 · 3mo ago +28.85%α +26.12% · $115.73
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Rhythm Pharmaceuticals announced that its CEO and CFO will participate in fireside chats at the Jefferies Global Healthcare Conference (June 4) and Goldman Sachs 47th Annual Global Healthcare Conference (June 8). This is a routine investor relations event with no new financial data, clinical updates, or regulatory decisions disclosed.
Key Facts
- CFO Hunter Smith to speak at Jefferies Global Healthcare Conference on June 4, 2026 at 12:50 p.m. ET
- CEO David Meeker to speak at Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026 at 1:20 p.m. ET
- Webcasts will be available on the company's investor relations page with replays for 30 days
- No financial results, guidance, clinical data, or regulatory updates were provided in this release
Financial Impact
No financial impact, this is a routine conference participation announcement with no material financial data disclosed.
Risk Factors
- No new clinical or financial data, stock may be range-bound until next catalyst
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3300998 |
Track record
26 reports on RYTM
9 of 14 bullish or bearish reports moved the stock their way by T+5. Best: +32.06% at T+60 after the May 1, 2026 report. 11 of 14 went positive at some point.
Filters
- Nov 16, 2026today Press Release Bullish 5/10 Entry $107.48 Now $107.48 +0.00% settles Nov 24
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
- Nov 4, 202612d ago Press Release Bullish 5/10 Entry $110.68 to $112.16 Now $107.48 −2.89% ▲ +1.34% +2.25% vs SPY
- Nov 3, 202613d ago 8-K Bullish 6/10 No price data
- Nov 3, 202613d ago Press Release Bullish 6/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
- Nov 2, 202613d ago Press Release Neutral 5/10 Entry $86.44 to $113.95 Now $107.48 +24.34% ▲ +31.83% +32.41% vs SPY
- Oct 13, 20264w ago Press Release Bullish 6/10 Entry $86.71 to $88.62 Now $107.48 +23.95% ▲ +2.20% +1.75% vs SPY
- Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $86.61 to $90.20 Now $107.48 +24.10% ▲ +4.14% +5.30% vs SPY
- Sep 14, 20269w ago 144 Bearish 5/10 Entry $96.77 to $99.27 Now $107.48 −11.07% ▼ −2.58% −0.47% vs SPY
- Aug 17, 202613w ago Insider Cluster Bearish 6/10 Entry $115.25 to $113.35 Now $107.48 +6.74% ▲ +1.65% +1.45% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers